<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022607</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068834</org_study_id>
    <secondary_id>CCC-PHII-30</secondary_id>
    <secondary_id>CHNMC-PHII-30</secondary_id>
    <secondary_id>CHNMC-IRB-01006</secondary_id>
    <secondary_id>NCI-2712</secondary_id>
    <nct_id>NCT00022607</nct_id>
  </id_info>
  <brief_title>Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or deliver cancer-killing substances to them. Thalidomide may stop the growth&#xD;
      of cancer cells by stopping blood flow to the tumor. It is not yet known whether bevacizumab&#xD;
      works better with or without thalidomide for multiple myeloma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is to see if bevacizumab works better with or without&#xD;
      thalidomide in treating patients who have relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the response rate and time to progression in patients with relapsed or&#xD;
           refractory multiple myeloma treated with bevacizumab with or without thalidomide.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the effects of these regimens on histological and molecular biomarkers of&#xD;
           angiogenesis, tumor invasion, and cell death in these patients.&#xD;
&#xD;
        -  Correlate plasma and urine vascular endothelial growth factor and basic fibroblast&#xD;
           growth factor levels and other potential markers of angiogenesis and myeloma cell&#xD;
           proliferation with outcome in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the pharmacokinetics of thalidomide in these patients.&#xD;
&#xD;
        -  Compare the effects of these regimens on the psychological/physical well being of these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior&#xD;
      treatment with thalidomide (yes vs no).&#xD;
&#xD;
      Patients who have received no prior treatment with thalidomide are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43.&#xD;
           Patients also receive oral thalidomide once daily.&#xD;
&#xD;
        -  Arm II: Patients receive bevacizumab as in arm I. Patients who have received prior&#xD;
           treatment with thalidomide receive bevacizumab as in arm I.&#xD;
&#xD;
      Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed monthly for 3 months and then every 3-4 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 55-103 patients (16-32 who have received prior thalidomide,&#xD;
      16-32 in arm I, and 23-39 in arm II) will be accrued for this study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed progressing multiple myeloma&#xD;
&#xD;
               -  Stages I, II, or III&#xD;
&#xD;
               -  More than 25% increase in urine or plasma paraprotein levels&#xD;
&#xD;
               -  More than 5% malignant plasma cell involvement in bone marrow&#xD;
&#xD;
          -  Smoldering myeloma is eligible provided there is evidence of progressive disease&#xD;
             requiring therapy&#xD;
&#xD;
               -  At least 25% increase in M protein levels or Bence Jones excretion&#xD;
&#xD;
               -  Hemoglobin no greater than 10.5 g/dL&#xD;
&#xD;
               -  Frequent infections&#xD;
&#xD;
               -  Hypercalcemia&#xD;
&#xD;
               -  Rise in serum creatinine above normal on 2 separate occasions&#xD;
&#xD;
          -  Nonsecretory multiple myeloma that is bidimensionally measurable by MRI or CT scan is&#xD;
             eligible provided the disease site is new or has shown an increase in M protein levels&#xD;
             or Bence Jones excretion is greater than 30% from baseline&#xD;
&#xD;
          -  No prior or concurrent CNS involvement with primary or metastatic tumor&#xD;
&#xD;
          -  No nonquantifiable monoclonal proteins or IgM peaks unless there is evidence of&#xD;
             bidimensionally measurable disease by MRI or CT scan&#xD;
&#xD;
          -  No history of hemorrhagic tumor or hemorrhagic metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Absolute neutrophil count ≥1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
          -  No hemorrhagic illness within the past 3 weeks&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  aPTT &lt; 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Calcium ≤ 12 mg/dL&#xD;
&#xD;
          -  No nephrotic syndrome&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No active coronary artery disease&#xD;
&#xD;
          -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  No grade II or greater peripheral vascular disease (i.e, ischemic rest pain,&#xD;
             non-healing ulcer, or tissue loss)&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No history of deep venous thrombosis&#xD;
&#xD;
          -  No vascular illness within the past 3 weeks&#xD;
&#xD;
          -  No arterial thromboembolic event within the past 6 months, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No history of pulmonary embolus&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior malignancy unless the patient has been in complete remission for at&#xD;
             least 2 years&#xD;
&#xD;
          -  No peripheral neuropathy or CNS abnormalities ≥ grade 2&#xD;
&#xD;
               -  Patients with prior exposure to thalidomide and assigned to arm I may have grade&#xD;
                  2 peripheral or CNS abnormalities&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No trauma within the past 3 weeks&#xD;
&#xD;
          -  No significant inflammatory illness within the past 3 weeks&#xD;
&#xD;
          -  No known hypersensitivity to Chinese hamster ovary cell products&#xD;
&#xD;
          -  No known hypersensitivity to other recombinant human or humanized antibodies and/or&#xD;
             positive human antimurine antibodies/human antichimeric antibodies&#xD;
&#xD;
          -  No other significant medical, psychological, or social problem that would preclude&#xD;
             study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for at least 2 weeks before and&#xD;
             during study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  Prior nonmyeloablative transplantation allowed provided the following are true:&#xD;
&#xD;
               -  Patient is not receiving concurrent immunosuppressive therapy&#xD;
&#xD;
               -  Patient has no signs of graft-versus-host disease&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed if started at least 4 weeks prior to study entry&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 5 prior chemotherapy regimens&#xD;
&#xD;
               -  Thalidomide, steroids, and interferon are not considered part of prior regimens&#xD;
&#xD;
               -  Mobilization with chemotherapy followed by either single or tandem autologous&#xD;
                  transplantation is counted as 1 prior regimen&#xD;
&#xD;
               -  Mobilization with chemotherapy followed by autologous and subsequent&#xD;
                  nonmyeloablative HLA-matched sibling allogeneic transplantation is counted as 1&#xD;
                  prior regimen&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior steroids&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior surgery, including biopsy of a visceral organ&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 10 days since prior anticoagulants, including aspirin&#xD;
&#xD;
          -  At least 2 days since prior nonsteroidal anti-inflammatory agents&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2004</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

